Equity
€2.5m ▼ 4.0%
PEETERS PHARMA paid out €1.0m in dividends. That is 112% of the 2024 profit.
PEETERS PHARMA
Lifetime
18 annual accounts with figures on one time axispeak €745,136 (2018)
-not published
lowest -€109,075 (2009)
€893,642▲ 94.6%
peak €2.6m (2023)
€2.5m▼ 4.0%
€9.6m▲ 27.2%
peak 54.9 FTE (2024)
54.9 FTE▲ 23.4%
Board3 names since 2021
1 directorpeeters mathieu management
Owners4 names in the annual accounts
Documentsfilings and deeds
23-06-202538 days before the deadline
2024financial year
Turnover from €23.7m to €37.3mResult from €459,317 to €893,642Staff from 44.5 FTE to 54.9 FTEDividend €1.0mDebts from €7.5m to €9.6m
Key points
from the 2024 annual accountsResult
€893,642 ▲ 94.6%
The result rose in 2024 from €459,317 to €893,642.
Debts
€9.6m 79% of the balance sheet
Financial debts 29%Suppliers 36%Taxes and wages 9%Other 26%
€3.4m of the debts are secured on the company's own assets. In 2022 that was €3.6m.
Staff
65 employees on 31-12-2024
In 2024, 27 people joined and 30 left. On top of that, 2.9 agency workers worked there on average.
Payment terms
40 days to suppliers
PEETERS PHARMA pays its suppliers 21 days earlier than in 2023. Customers pay 5 days earlier.
Filings
18 annual accounts 99 days past the deadline
2025 accounts not filed: deadline was 31-07-2026.
Checked score
54
Fair
Financially stronger than 51% of medium-sized companies in retail trade (NACE 47)
Probability in this band: 1.5% to 4.2%
Bankruptcy probability within 12 months
2.1% Moderate
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.4% across 385 companies (NACE 47, medium-sized).
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.4%lowest value
01-2025: 0.4%● unchanged vs 12-2024lowest value
02-2025: 0.4%● unchanged vs 01-2025
03-2025: 0.4%● unchanged vs 02-2025
04-2025: 0.4%● unchanged vs 03-2025
05-2025: 0.4%● unchanged vs 04-2025
06-2025: 0.4%● unchanged vs 05-2025
07-2025: 0.4%● unchanged vs 06-2025
08-2025: 0.4%● unchanged vs 07-2025
09-2025: 0.4%● unchanged vs 08-2025
10-2025: 0.4%● unchanged vs 09-2025
11-2025: 0.4%● unchanged vs 10-2025
12-2025: 0.4%● unchanged vs 11-2025
01-2026: 0.4%● unchanged vs 12-2025
02-2026: 0.4%● unchanged vs 01-2026
03-2026: 0.4%● unchanged vs 02-2026
04-2026: 0.4%● unchanged vs 03-2026
05-2026: 0.4%● unchanged vs 04-2026
06-2026: 0.4%● unchanged vs 05-2026
07-2026: 0.5%▲ +0.1 percentage points vs 06-2026
08-2026: 1.1%▲ +0.6 percentage points vs 07-2026
09-2026: 1.4%▲ +0.3 percentage points vs 08-2026
10-2026: 2.1%▲ +0.7 percentage points vs 09-2026highest value
11-2026: 2.1%● unchanged vs 10-2026highest value
Financial strengthAverage
Score breakdown
raises risk
Figures for financial year 2024 (filed on 26-06-2025)
Liquidity: current ratio 1.11, cash €731,935
lowers risk
Founded in 2007
Profit of €893,642 (financial year 2024)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, medium-sized). It does better than 43% of them on solvency, 33% on liquidity, 64% on profitability and 63% on growth.
The bankruptcy probability was computed on 06-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2024.
Of the companies with a bankruptcy probability in the moderate class on 30-06-2025, 2.4% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 172 companies had the same profile as PEETERS PHARMA has now. Each dot is one company, two years later.
96.5%
were still trading
3.5%
stopped another way
0.0%
went bankrupt
The bankruptcy probability of PEETERS PHARMA itself is higher: 2.1% within 12 months. It rests on far more data about PEETERS PHARMA than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 172 companies, not a prediction for PEETERS PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €130,000 on 30-day terms, only on tighter conditions: an expected filing is missing beyond Checked's processing allowance
Liquidity is tight, with a current ratio of 1.11 (1.21 in 2023), below the usual 1.5. Short-term debt is 58.5% and cash 6% of total assets. 79.1% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Annual accounts not filed
The financial year that closed on 31-12-2025 was due at the National Bank by 31-07-2026. Nothing is on record, 99 days later.
NBB · 10 filingsPosition against the passed deadline
31-12-2025 year end31-07-2026 deadline07-11-2026 today
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 23-06-2025, 38 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
not filed
2024
38 days early
2023
on the day
2022
on the day
2021
25 days early
2020
3 days late
2019
2 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 6 accounts on average 10 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (1)
Board and ownership
- peeters mathieu management 100%score 51equity €8.7m (2024) · 2024 annual accounts of peeters mathieu management
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0888243054
New establishment in Genk
Peeters Pharma Viata, Seinhuisstraat 7
Appointment: RSM InterAudit (statutory auditor)
Permanent representative: MATHIEU PEETERS · General meeting of 06-12-2022 · Gazette deed
Merger: Apotheek Mathieu Peeters takes over Apotheek Peeters Oudsbergen NV
Company renamed to PEETERS PHARMA · New name: PEETERS PHARMA · Resignation: PHARMA FORCE NV (director) · General meeting of 29-07-2022 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PEETERS PHARMA Kinrooi | €37.3m | 4.1% | 20.9% | 54.9 |
| MEDACTA BELGIUM Nivelles | €24.0m | 4.0% | 27.9% | 45.2 |
| OXYCURE Fernelmont | €13.8m | 2.0% | 21.6% | 60.1 |
| PHARMACIE HOUBA Brussels | €21.2m | 9.0% | 49.0% | 39.8 |
| FARMAZORG Oudenburg | €19.5m | 1.1% | 35.6% | 76.5 |
| PHI-BIS Malle | €16.2m | 4.7% | 41.8% | 41 |
| APOTHEEK DESSEIN Beernem | €35.7m | 2.5% | 34.1% | 61.8 |
Grey: the largest companies of the sector (retail trade (NACE 47)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as PEETERS PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €6.2m and €11m, founded between 1979 and 2011.
Official details
Source: KBO- Status
- Active since 19-03-2007Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2024
- Establishment units
- 2.161.501.0823640 Kinrooi, since 19-03-2007
- 2.338.552.7091160 Auderghem, since 29-07-2022and 11 others
- Financial year end
- 31 December
- Peppol
- Reachable since 19-06-2025
Annual accounts 2024
- €12.1m▲ 19.1%
- Employeeson 31-12-2024
- 65▼ 4.4%
- Filing
- Filed on 23-06-2025
Insights on PEETERS PHARMA
PEETERS PHARMA has existed since 2007. The present size dates from 2011. The gross margin rose that year from €93,826 to €259,869.
Solvency fell in 2024 from 25.9% to 20.9% because of the dividend.
peeters mathieu management holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PEETERS PHARMA
- What is the company number of PEETERS PHARMA?
- The company number of PEETERS PHARMA is 0888.243.054. The VAT number is the same number with BE in front: BE 0888.243.054.
- Where is PEETERS PHARMA based?
- The registered office is at Breeërsteenweg 348, 3640 Kinrooi.Company details
- What does PEETERS PHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of PEETERS PHARMA?
- PEETERS PHARMA is a private limited company (BV).
- When was PEETERS PHARMA founded?
- PEETERS PHARMA was founded on 19-03-2007.
- Is PEETERS PHARMA still active?
- Yes, PEETERS PHARMA is an active enterprise in the KBO register.
- How many employees does PEETERS PHARMA have?
- PEETERS PHARMA had an average of 54.9 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
- Which joint committee does PEETERS PHARMA fall under?
- In its 2024 annual accounts, PEETERS PHARMA states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of PEETERS PHARMA?
- The turnover of PEETERS PHARMA was €37.3m in financial year 2024, according to the filed annual accounts.
- Is PEETERS PHARMA profitable?
- In financial year 2024, PEETERS PHARMA made a profit of €893,642.
- Where can I find the annual accounts of PEETERS PHARMA?
- PEETERS PHARMA filed 18 annual accounts with the National Bank of Belgium, the latest for financial year 2024.
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies
See how customers, suppliers and banks see your own company and what to improve first.